For a patient walking into a doctor's office, the most critical moment often happens before the exam begins. It's the moment they try to recall every symptom, every medication, and every relevant detail from a complex medical history, all while the clock is ticking. Dr. Steven Charlap, a physician for four decades, believes this is where the healthcare system fails, and where a preventable misdiagnosis can take root. His startup, Medome, is building an AI-driven health intelligence app designed to give patients a fighting chance in that moment, by preparing them to be their own best advocate [Medome homepage].
The clinical note as a patient tool
Medome's core intervention is deceptively simple. It asks users to input their complete medical history and current symptoms. Then, its system, which the company says is powered by over 500 proprietary algorithms, generates a structured clinical note and a list of pointed questions for the upcoming appointment [PR.com, Nov 2025]. This isn't just a digital checklist. The platform aims to function as an AI scribe for the patient, creating a living document that can be shared with the physician. During the visit, the app can record the conversation and, according to the company, provide a real-time second opinion by flagging potential discrepancies between the doctor's assessment and the patient's reported history [PR Newswire, Nov. 2022]. The bet is that a better-prepared patient leads to a more efficient, accurate consultation.
A founder's mission and a quiet launch
Charlap's motivation is deeply personal. He founded Medome after losing his brother, a cardiologist, to what he describes as a preventable misdiagnosis [Medome homepage]. He is joined by co-founder Paul Battle, a development and sales executive [LinkedIn, retrieved 2026]. The company, headquartered in Boca Raton and founded in 2025, operates with a notably low public profile. There is no verifiable funding history or named institutional investors in the public record. Its traction claims rest on company statements, including being "clinically validated with thousands of real patients" and having been used by over 20,000 users [PR Newswire, Nov. 2022] [FinanceWire, Dec 2025]. This places Medome in the large and challenging category of direct-to-consumer health apps, where user adoption and clinical proof are the primary currencies.
The crowded field of digital health advocates
The market for tools that help patients manage health data and navigate care is not empty. Medome's approach, however, carves out a specific niche focused on pre-visit preparation and misdiagnosis prevention, rather than general wellness tracking or chronic condition management. The company positions its product as the first AI-powered personal health record of its kind [PR Newswire, Dec 2025]. Yet, the path forward is lined with significant hurdles that go beyond technology.
- Regulatory positioning. While the app consolidates records and offers guidance, it carefully avoids providing a standalone diagnosis, which would trigger FDA scrutiny as a medical device. Its value is framed as a patient education and communication aid.
- The adoption puzzle. Convincing consumers to consistently input detailed medical data into a new app is a perennial challenge. The value proposition must overcome significant inertia and privacy concerns.
- Proof of outcomes. The most compelling case for Medome would be peer-reviewed data showing its use leads to statistically significant reductions in diagnostic errors or improvements in care quality. That level of validation is not yet present in the public domain.
The company's connection to Charlap's other venture, SOAP Health, which shares a focus on diagnostic accuracy, suggests a broader strategic ecosystem may be in play [Forbes, retrieved 2026].
What to watch in the next year
For Medome, the coming months will be about moving from claim to demonstrated evidence. Key signals will include any formal partnerships with healthcare providers or payer organizations, which could serve as a distribution channel and a source of validation. A published study, even a small retrospective one, on the app's impact on diagnostic accuracy would significantly bolster its medical credibility. Finally, any seed funding round would provide resources to tackle the immense consumer marketing challenge and potentially expand the team beyond its founding duo.
The standard of care for a patient today facing a complex health concern is often a fragmented one. Medical histories are scattered across different health systems, crucial details are forgotten in the stress of a 15-minute appointment, and the burden of synthesizing information falls entirely on the physician in that limited window. For individuals dealing with chronic, multi-system, or rare diseases, this fragmentation can lead to years of diagnostic odysseys. Medome's ambition is to place a structured, intelligent summary directly into the hands of the person who needs it most,the patient sitting in the waiting room.
Sources
- [Medome homepage, retrieved 2024] Medome homepage | https://medome.ai
- [PR Newswire, Nov. 2022] MEDOME RELEASES SOLUTION TO END MISDIAGNOSIS IN PRIMARY CARE | https://www.prnewswire.com/news-releases/medome-releases-solution-to-end-misdiagnosis-in-primary-care-will-save-100s-of-thousands-of-lives-annually-302679821.html
- [PR.com, Nov 2025] Medome launch announcement | https://www.pr.com/nov-2025
- [FinanceWire, Dec 2025] Medome Launch Heralds the End of Medical Misdiagnoses and Lost Lives | https://financewire.com/2025/12/19/medome-launch-heralds-the-end-of-medical-misdiagnoses-and-lost-lives/
- [LinkedIn, retrieved 2026] Paul Battle - Medome | https://www.linkedin.com/in/paulbattle/
- [Forbes, retrieved 2026] How AI Is Changing Primary Care Forever | Dr. Steven Charlap | https://books.forbes.com/author-podcasts/smarter-healthcare-with-ai/revolutionizing-primary-care-with-ai-a-conversation-with-dr-steven-charlap-part-two/
- [PR Newswire, Dec 2025] Medome launch coverage | https://www.prnewswire.com/news-releases/medome-launch-heralds-the-end-of-medical-misdiagnoses-and-lost-lives-302999999.html